Objectives: This study aimed to examine the association of angiotensin-converting enzyme (ACE) and glutathione S-transferase (GST) gene polymorphisms with body mass index (BMI) in hypertensive North Indians. Methods: This case-control study was carried out between May 2013 and November 2014 at the Era's Lucknow Medical College & Hospital, Lucknow, India, and included 378 subjects divided into three groups. One group constituted 253 hypertensive individuals (sustained diastolic blood pressure of >90 mmHg and systolic blood pressure of >140 mmHg) who were subcategorised according to normal (<25 kg/m 2 ) or high (≥25 kg/m 2 ) BMI. The third group consisted of 125 age-, gender-and ethnically-matched normotensive controls with a normal BMI. Gene polymorphisms were evaluated by polymerase chain reaction. The genotypic and allelic frequency distribution among both groups were analysed. Results: A significant difference was found between GST theta 1-null and GST mu 1-positive genotype frequencies among the hypertensive overweight/obese individuals and controls (P = 0.014 and 0.033, respectively). However, no difference was observed in the frequency of ACE polymorphisms. ACE insertion/insertion genotype (P = 0.006), insertion and deletion alleles (P = 0.007 each) and GST theta 1-null and GST theta 1-positive genotypes (P = 0.006 each) were found to differ significantly between hypertensive cases and controls, regardless of BMI. Conclusion: ACE and GST gene polymorphisms were not associated with BMI but were significantly associated with hypertension among the studied group of North Indians. 
H ypertension and obesity are emerging global health concerns. 1 Many epidemiological studies have shown an association between these medical conditions. 2, 3 Hypertension predisposes individuals to future weight gain as compared to their normotensive counterparts, which means that even hypertensive individuals at a normal weight are at significantly higher risk of becoming obese. 4 The body mass index (BMI) is used to classify individuals according to various weight categories. A high BMI is associated with an increased burden of diabetes, hypertension and cardiovascular diseases. 1 Aside from environmental and lifestyle factors, BMI is also influenced by genetic factors. Research has confirmed the involvement of different genetic polymorphisms in the metabolism and appetite of predisposed individuals, thus causing them to become overweight or obese. 1 More than 41 loci on the human genome have been linked with the development of obesity. 1 The angiotensin-converting enzyme (ACE) is part of the renin-angiotensin system, which is responsible for regulating blood pressure and the balance of fluids and salts inside the body. Engeli et al. suggested that components of the renin-angiotensin system might be involved in the development of obesity and associated hypertension. 5 The insertion/deletion polymorphism occurs in intron 16 of the ACE gene due to the presence or absence of a 278 base pairs (bp) Arthrobacter luteus repetitive sequence. 6 This polymorphism has been found to drastically affect ACE activity where the deletion/deletion genotype increases ACE activity while the insertion/insertion genotype decreases activity. 7 A study conducted in Pakistan showed the association of the ACE gene polymorphism with obesity, suggesting a role for the deletion allele in adipogenesis and adipocyte metabolism. 8 Hirata et al. confirmed the role of oxidative stress in linking obesity with hypertension. 9 Systemic oxidative stress levels increase obesity, which may lead to the development of obesity-related hypertension. Glutathione S-transferase (GST) plays a major role in combating reactive oxygen species, thus protecting the body against its harmful effects. 10 Evidence also indicates the involvement of oxidative stress with the pathogenesis of hypertension. 9 Among humans, the gene coding for GST mu 1 (GSTM1) and GST theta 1 (GSTT1) are located on chromosomes 1p13.3 and 22, respectively. Previous studies have demonstrated that GST polymorphisms were not associated with BMI in diabetic North Indians or with weight gain in schizophrenic Koreans. 11, 12 Since there is a close link between hypertension and obesity, this study sought to investigate the association of ACE and GST gene polymorphisms with BMI among a selected group of hypertensive North Indians.
Methods
This case-control study was carried out between May 2013 and November 2014 at the Era's Lucknow Medical College & Hospital, Lucknow, India. A total of 253 subjects with either a recent diagnosis or history of hypertension were recruited from the Department of Medicine at Era's Lucknow Medical College & Hospital. These patients mostly resided in Lucknow and adjoining areas, including Hardoi and Barabanki. A diagnosis of hypertension was based on sustained diastolic blood pressure of >90 mmHg and systolic blood pressure of >140 mmHg. Hypertensive patients were subsequently subcategorised according to BMI into normal weight (BMI <25 kg/m 2 ) or overweight/obese (≥25 kg/m 2 ) groups. As a control group, 125 age-, gender-and ethnically-matched normotensive individuals of normal weight (BMI <25 kg/m 2 ) were recruited for inclusion in the study. Patients who visited the outpatient clinics for minor illnesses and with no history of major clinical diseases were recruited as controls. Subjects in either group with a history of smoking or evidence of cancer, organ dysfunction or metabolic disease were excluded. The sample size calculations were based on the proportion of ACE genotypes among the cases and controls using the following formula:
Based on a 95% level of significance and 80% expected power (20% type 2 error), the minimum sample size was 103 in each group. Subject to the ) was used to calculate the BMI of each participant. WHR was calculated by dividing the waist circumference at the narrowest point above the hip by the hip circumference at its greatest gluteal protuberance. Serum triglycerides were measured using the glycerol phosphate oxidase-peroxidase-amidopyrine method while serum cholesterol was measured by the cholesterol oxidase-peroxidase method. Highdensity lipoprotein cholesterol was measured by the immunoinhibition method using the Erba XL-300 fully automated chemistry analyser (Erba Diagnostics Mannheim GmbH, Mannheim, Germany). Very lowdensity lipoprotein levels were estimated by dividing measured triglycerides by 5 mg/dL units. Low-density lipoprotein cholesterol levels were estimated using the Friedewald formula. 13 The DNA extraction was performed using 3 mL of venous blood collected from all participants in 0.5 M ethylenediaminetetraacetic acid tubes. A standard phenol-chloroform extraction method was used to isolate genomic DNA from the blood samples. 14 The DNA concentration was determined by a spectrophotometer and samples were stored at -20 °C .
ACE insertion/deletion polymorphisms (rs464994) were analysed by genomic DNA amplification using polymerase chain reaction (PCR) technology. 15 PCR amplification was conducted in a total volume of 20 µL using: 10 pmol each of forward primer 5'-CT-GGAGACCACTCCCATCCTTTCT-3' and reverse primer 5'-GATGTGGCCATCTTCGTCAGAT-3'; 200 ng of genomic DNA; 3 mM of magnesium chloride; 50 mM of potassium chloride; 10 mM of trisaminomethane hydrochloride at a pH of 8.4; 0. 5 15 Primers for GSTM1 were 5'-AACTCCCTGAAAAGCTAAAGC-3' and 5'-GTT-GGGCTCAAATATACGGTGG-3' , while primers for GSTT1 were 5'-TTCCTTACTGGTCCTCACATCT C-3' and 5'-TCACCGGACATGGCCAGCA-3' . To avoid false-negative readings, β-globin was used as an internal control. Primers for β-globin were 5'-CAACTTCATCCACGTTCACC-3' and 5'-GAA GAGCCAAGGACAGGTAC-3' . PCR amplification was conducted in a total volume of 25 μL using: 10 pmol of each primer; 100 ng of genomic DNA; 2.5 mmol/L of magnesium chloride; 0.2 mmol/L each of deoxyribonucleotide triphosphate; and 1 U of Taq polymerase (Bioline Reagents Ltd). The PCR amplification was performed using an initial denaturation at 94
°C for five minutes, followed by 30 cycles at 94 °C for one minute, 64 °C for one minute,
72
°C for one minute and a final extension of 72 °C for seven minutes. Amplified products were separated on a 1.5% agarose gel stained with 0.5 μg/mL of ethidium bromide and visualised using a bioimaging and gel documentation system (UVP LLC). Direct sequencing was carried out for approximately 10% of all samples for both polymorphisms studied and genotyping for 20% of the samples was further duplicated. The results were verified by two individual laboratory technicians to confirm genotyping results. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS), Version 12 (IBM Corp., Chicago, Illinois, USA). Variables were tested for normality using the KolmogorovSmirnov test. Variables with a normal distribution were expressed as means ± standard deviation while variables with a non-normal distribution were expressed as medians and interquartile ranges and were log transformed before statistical analysis. A Chi-squared test was used to compare genotyping data between cases and controls. A P value of ≤0.050 was considered significant. The odds ratio (OR) and 95% confidence interval (CI) was calculated to test the relative risk for association. Other variables were compared using the Student's t-test for normallydistributed variables.
Ethical approval for this study was granted by the Institutional Ethical Committee of the Department of Medicine at Era's Lucknow Medical College & Hospital (#ELMC/E-1/3942). Written informed consent was obtained from each subject prior to data collection.
Results
A total of 378 patients were included in this study, Figure 1 ]. For GST genetic polymorphisms, the band sizes observed were 215 bp, 480 bp and 268 bp for GSTM1, GSTT1 and β-globin, respectively [ Figure 2 ]. Negligible discrepancy in genotyping was observed.
The genotype frequencies of ACE insertion/ deletion, deletion/deletion and insertion/insertion genotypes among the hypertensive overweight/obese group and the hypertensive normal weight group were 53.34%, 19.33% and 27.33% and 54.37%, 16.50% and 29.13%, respectively (OR = 0.96, 1.22 and 0.91; 95% CI = 0.56-1.66, 0.59-2.49 and 0.50-1.67; P = The presence or absence of GST mu 1 (GSTM1) and GST theta 1 (GSTT1) was detected by 480 base pairs (bp) and 210 bp bands, respectively. β-globin was considered an internal control at 260 bp. Lanes 1 and 7 show GSTM1-and GSTT1-null genotypes, respectively, and lanes 2-5 show GSTM1 and GSTT1 wild-type genotypes. Lane 4 is a 100 bp ladder. Tables 2 and 3 ]. The GSTM1-null genotype frequency was 33.33% for the hypertensive overweight/obese group, while it was 36.89% and 45.60% for the hypertensive normal weight and control groups, respectively (OR = 0.84 and 0.61; 95% CI = 0.47-1.50 and 0.35-1.07; P = 0.559 Tables 2 and 3 ].
The ACE insertion/insertion genotype frequency among the combined overweight/obese and normal weight hypertensive groups was 28.07% compared to 13.60% in the control group (OR = 2.41; 95% CI = 1.27-4.57; P = 0.006). The deletion/deletion genotype frequency was 17.18% among hypertensives compared to 27.20% among healthy controls (OR = 0.59; 95% CI = 0.34-1.04; P = 0.068). Among the hypertensives, frequencies of the insertion and deletion alleles were 55.14% and 44.86%, respectively, compared with 43.20% and 56.80% in the control group, respectively (OR = 1.59 and 0.63; 95% CI = 1.13-2.24 and 0.45-0.88; P = 0.007 each). The frequencies of the GSTT1-and GSTM1-null genotypes in the hypertensive groups were 14.69% and 34.78%, respectively (OR = 4.09 and 0.63; 95% CI = 1.40-11.96 and 0.39-1.03; P = 0.006 and 0.062). A significant difference was found between the GSTT1-null (14.69% versus 4.00%) and -positive (85.37% versus 96.00%; OR = 0.24; 95% CI = 0.08-0.71; P = 0.006) genotypes among the hypertensive groups in comparison to the control group. However, there was a non-significant difference between frequencies of GSTM1-positive genotypes (65.22% versus 54.40%; OR = 1.59; 95% CI = 0.97-2.58; P = 0.062) [ Table 4 ].
Discussion
Hypertension and obesity may have a mutual or reciprocal relationship, where the presence of one potentially leads to the other. 4 Studies have shown that the prevalence of hypertension is directly related to a higher BMI. 2, 3 In the current study, lipid profile variables (including serum cholesterol, triglycerides, low-and very low-density lipoproteins and WHR) were higher among the hypertensive individuals than the healthy controls, regardless of BMI category. Various studies have demonstrated increased plasma renin activity and plasma angiotensinogen, angiotensin II and aldosterone levels in obese individuals. [16] [17] [18] Cooper et al. pointed out that the ACE insertion/ deletion polymorphism was linked to changes in ACE levels, but was inconsistently associated with BMI. A study of a Saudi population noted a higher frequency of the mutant deletion allele in hypertensive cases with a BMI of ≥30 kg/m 2 in comparison to controls, although the difference was not significant. 20 However, this result was reversed in the current study, as the frequency of the deletion allele among the hypertensive overweight/obese group was significantly lower than the control group. A similar study performed on Korean women also confirmed this finding (P = 0.063). 21 Similarly, Passaro et al. showed that subjects with different polymorphisms in the ACE gene did not show significant variability in BMI. 22 The frequency of the ACE deletion/deletion genotype among hypertensive overweight/obese individuals in the current study (19.33%) was similar to that found among an overweight Pakistani population (18.00%). 8 The frequency of the ACE insertion/ insertion genotype in the hypertensive overweight/ obese group of the current study (27.33%) was similar to that found among obese Pakistani individuals (26.00%); however, it was lower than the frequency found among overweight Pakistanis (32.00%). 8 Eisenmann et al. reported that children with the ACE deletion/deletion genotype had a higher BMI compared to insertion/insertion carriers; 23 this is consistent with the results obtained in the current study when comparing the hypertensive groups according to BMI, although this was not found to be significant. These results are contradictory to another report which demonstrated that the mutant deletion allele was associated with a low BMI. 24 On further comparison of the hypertensive overweight/obese and control groups in the current study, a significant difference was found between the frequency of the insertion/insertion genotype and between the allele frequencies of insertion and deletion alleles. While no significant association was found between the ACE insertion/deletion polymorphism and BMI in the hypertensives, a significant association was observed with hypertension. This suggests that the ACE insertion/deletion polymorphism affects hypertension as opposed to BMI, with carriers of the insertion/ insertion genotype being more prone to hypertension. The insertion/insertion genotype frequency in the combined North Indian hypertensive population of the current study (28.07%) was similar to that found in hypertensive Pakistanis (29.30%) and another North Indian population (28.62%). 15, 25 There was a significant association between the ACE insertion/insertion genotype and hypertension; this contrasts with the results of a study conducted among South Indians, although it is similar to that of the other study on North Indians. 15, 26 The current study found an association between the ACE deletion/deletion genotype and hypertension, although this was not significant. The frequency of this genotype among hypertensives in the current study (17.18%) was higher than that found for Malaysian and Bangladeshi individuals (10.76% and 11.40%, respectively); however, a Chinese population had a lower frequency. [27] [28] [29] The insertion and deletion alleles were significantly related to hypertension in the current study, which correlates with the findings of a similar North Indian study. 15 A positive correlation has been reported between various obesity variables like BMI and WHR, including oxidative stress markers such as reduced erythrocyte glutathione. 30 In the current study, significant variation was found between the GSTT1-null genotype frequency among the hypertensive overweight/ obese and control groups. Similarly, the frequency of the GSTM1-positive genotype was significantly higher in the hypertensive overweight/obese subjects. However, this difference was not significant when compared with the hypertensive normal weight group. The frequencies of the GSTM1-and GSTT1-null genotypes among hypertensive overweight/obese subjects in the present study (33.33% and 13.33%, respectively) were lower than those of non-Hispanics (45.30% and 81.60%, respectively), African Americans (72.20% and 76.20%, respectively) and Hispanics (46.70% and 81.70%, respectively) with higher BMIs. 31 In contrast, the frequencies of GSTM1-and GSTT1-positive genotypes were higher when compared to overweight/obese non-Hispanics (54.70% and 18.40%, respectively), African Americans (27.80% and 23.80%, respectively) and Hispanics (53.30% and 18.30%, respectively). 31 The GSTM1-and GSTT1-positive genotype frequencies were somewhat higher among the overweight/obese hypertensives in the current study than for hypertensives of a normal weight, while the null genotype frequencies were lower among the former than the latter. However, these differences were not significant. The GSTM1-and GSTT1-positive genotype findings were similar across all three groups; nevertheless, there was a slightly higher although nonsignificant frequency in the hypertensive overweight/ obese group than the hypertensive normal weight group. No association was found between GST polymorphisms and BMI in Indian diabetic patients with null and positive GST genotypes. 11, 32 Similarly, in Korean schizophrenic patients, no association was observed between GST polymorphisms and druginduced weight gain. 12 In view of these results, it can be concluded that GST polymorphisms are not associated with a higher BMI among hypertensive patients.
In the present study, a significant difference was found between the GSTT1-null and -positive genotypes among hypertensives in comparison to control subjects. However, frequencies of GSTM1-null and-positive genotypes were not significant. The frequencies of the GSTT1-and GSTM1-null genotypes among hypertensive patients in the current study (14.69% and 34.78%, respectively) were lower in comparison to findings from Arab (30.00% and 60.00%, respectively), Chinese (58.10% and 60.00%, respectively) and Korean (55.40% and 51.80%, respectively, and 61.20% and 62.40%, respectively) populations, but similar to findings from another North Indian study (11.59% and 34.05%, respectively). 15, [33] [34] [35] [36] In comparison, the GSTM1-positive genotype was found in 65.22% of the hypertensives in the current study; this was higher than the results from Arab (40.00%), Chinese (40.00%) and Korean (48.20% and 37.60%) populations, but again similar to results from a North Indian study.
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Conclusion
Among the studied North Indian population, ACE and GST genetic polymorphisms (particularly ACE insertion/insertion and GSTT1-null and -positive genotypes) were significantly associated with hypertension but not BMI. Although they were not significantly associated with a higher BMI, ACE and GST polymorphisms may nevertheless be related to the development of hypertension in overweight or obese individuals.
